British Journal of Pharmacology · 2018 · 315 citations · 46 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyPharmacodynamicsStructure-activity RelationshipsAllosteric ModulationCannabinoid PharmacologyLigand BindingReceptor BindingReceptor PharmacologyReceptor-ligand InteractionsAllosteric Modulator BindingCannabinoid AgonistsCannabinoid Receptor PharmacologyCannabinoid Structure-activity RelationshipsNegative Allosteric ModulationNegative Allosteric ModulatorsOrthosteric InteractionsReceptor Binding Models
Background and Purpose We sought to understand why (−)‐cannabidiol (CBD) and (−)‐cannabidiol‐dimethylheptyl (CBD‐DMH) exhibit distinct pharmacology, despite near identical structures. Experimental Approach HEK293A cells expressing either human type 1 cannabinoid (CB 1 ) receptors or CB 2 receptors were treated with CBD or CBD‐DMH with or without the CB 1 and CB 2 receptor agonist CP55,940, CB 1 receptor allosteric modulator Org27569 or CB 2 receptor inverse agonist SR144528. Ligand binding, cAMP levels and βarrestin1 recruitment were measured. CBD and CBD‐DMH binding was simulated with models of human CB 1 or CB 2 receptors, based on the recently published crystal structures of agonist‐bound (5XRA) or antagonist‐bound (5TGZ) human CB 1 receptors. Key Results At CB 1 receptors, CBD was a negative allosteric modulator (NAM), and CBD‐DMH was a mixed agonist/positive allosteric modulator. CBD and Org27569 shared multiple interacting residues in the antagonist‐bound model of CB 1 receptors (5TGZ) but shared a binding site with CP55,940 in the agonist‐bound model of CB 1 receptors (5XRA). The binding site for CBD‐DMH in the CB 1 receptor models overlapped with CP55,940 and Org27569. At CB 2 receptors, CBD was a partial agonist, and CBD‐DMH was a positive allosteric modulator of cAMP modulation but a NAM of βarrestin1 recruitment. CBD, CP55,940 and SR144528 shared a binding site in the CB 2 receptor models that was separate from CBD‐DMH. Conclusion and Implications The pharmacological activity of CBD and CBD‐DMH in HEK293A cells and their modelled binding sites at CB 1 and CB 2 receptors may explain their in vivo effects and illuminates the difficulties associated with the development of allosteric modulators for CB 1 and CB 2 receptors. Linked Articles This article is part of a themed section on 8 th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc
46
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
Konstantin Arnold, Lorenza Bordoli, Jürgen Kopp et al. · Bioinformatics · 2005 · 7.1K citations · Full text
ZINC: A Free Tool to Discover Chemistry for Biology
John J. Irwin, Teague Sterling, Michael M. Mysinger et al. · Journal of Chemical Information and Modeling · 2012 · 2.6K citations · Full text
The SWISS-MODEL Repository and associated resources
Florian Kiefer, Konstantin Arnold, Michael Künzli et al. · Nucleic Acids Research · 2008 · 2K citations · Full text